secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027464
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q2 2023: cash $25.8M, net loss $3.8M; PUR1900 Phase 2b enrollment ongoing, topline Q3 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $25.8M as of June 30, 2023; projected runway into Q1 2025.
- Q2 revenue $1.8M (up from $1.3M YoY); net loss $3.8M ($1.04 per share).
- PUR1900 Phase 2b for ABPA enrolling; 13 sites active; topline data expected Q3 2024.
- IND filed for PUR3100 Phase 2 in acute migraine; partnership needed to start trial.
- Phase 1b data for PUR1800 in AECOPD presented; partnership opportunities being pursued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223027464/0001493152-23-027464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223027464/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer